Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease

Table 2 Characteristics of individual patient diagnosed with post-transplant lymphoproliferative disorder

Patient (gender)	Year of HT	HT to PTLD (yr)	EBV serologyat HT	EBV loadat PTLD	Organ involved in PTLD	CD20 positivity	EBER status of PTLD	Histological diagnosis	Treatment
1 (M)	1995	16	Positive	< 10000	Retroperitoneal lymph node	Neg	Neg	Hodgkin Lymphoma	Chemotherapy
2 (F)	1996	14	Positive	< 10000	Cervical Lymph node	Neg	Neg	Diffuse large B-cell lymphoma	Chemotherapy
3 (M)	1999	12	Positive	> 10000	Retroperitoneal lymph node	Pos	Neg	Polymorphic PTLD	Rituximab
4 (M)	2001	3	Positive	> 10000	Pharynx	Neg	Pos	Intermediate between Hodgkin and large cell lymphoma	Chemotherapy plus Radiation
5 (F)	2009	3	Negative	> 10000	Cervical Lymph node	Pos	Pos	Polymorphic PTLD	Rituximab
6 (F)	2000	14	Positive	< 1000	Brain-Temporal Lobe	Pos	Pos	Polymorphic PTLD	Rituximab
7 (M)	2000	3	Negative	< 10000	Small intestine	Pos	Pos	Polymorphic PTLD	Rituximab
8 (F)	2005	6	Positive	> 10000	Retroperitoneal lymph node	Pos	Pos	Large B-cell Lymphoma	Rituximab

HT: Heart transplant; Neg: Negative; Pos: Positive; EBER: Epstein-Barr virus encoded small RNA; PTLD: Post-transplant lymphoproliferative disorder.